Argos Therapeutics: A Cure For Cancer?

AGS-003 for metastatic renal cell carcinoma ((mRCC)) in Phase III with the full patient enrollment expected in Q2-2014. The final results should come out in the second half of 2016. The primary endpoint of the study is the overall survival.05/23/2015
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news